Core Viewpoint - The Hang Seng Healthcare Index increased by 2.2% last week, underperforming the broader market, with the CXO, biopharmaceutical, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Domestic investors have been increasing their holdings through the Hong Kong Stock Connect since September, while foreign investors' holdings have slightly decreased since mid-year, although both continue to focus on innovative drug companies [1] - Both domestic and foreign investors have increased their positions in service-related stocks, particularly those that may benefit from interest rate cuts, such as CXO companies [1] Group 2: Upcoming Events - The ESMO conference is scheduled for mid to late October, and the report suggests focusing on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995), which are expected to release significant data [1] Group 3: Investment Recommendations - The report recommends attention to the following sectors: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have abundant short-term catalysts and their valuations do not yet reflect the value of core products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and improving financing conditions [1]

Core Insights - The article discusses the competitive landscape of the investment trust sector in London, highlighting the strategies of activist investors like Daniel Loeb and Joe Bauernfreund, who focus on acquiring shares of companies trading at discounts to their liquidating values [1][2][3]. Group 1: Investment Strategies - AVI Global Trust, managed by Joe Bauernfreund, specializes in buying shares of companies and investment trusts that are undervalued, particularly those with significant assets [3][4]. - The trust has achieved an 11.8% compound annual return over 40 years, outperforming the ACWI global stock index by 2.4 percentage points [6]. - The article suggests that Japan presents a promising market for value investing, with small-company Japanese stocks expected to outperform other asset classes according to GMO's forecasts [6][13]. Group 2: Activist Investor Dynamics - Daniel Loeb's recent merger of his London-listed trust with an offshore insurance company faced opposition from dissident shareholders, leading to increased cash payouts to them [2][15]. - Joe Bauernfreund's approach involves targeting holding companies controlled by wealthy families, which often trade at significant discounts to their liquidating values [4][11]. - The article notes that many investors overlook the value in complex holding companies due to their perceived uninvestability [11]. Group 3: Specific Company Examples - News Corp is highlighted as a prime example of a holding company trading at a 41% discount to its liquidating value, with significant assets like the Wall Street Journal and a 61% stake in REA [5][11]. - Vincent Bolloré's conglomerate and Vivendi are also mentioned as trading at discounts, with Bolloré's complex corporate structure allowing for control over a diverse asset pool [10][11]. - Christian Dior, a holding company with a 2% public float, trades at an 18% discount to its net asset value, with AVI Global Trust holding some of its shares [12]. Group 4: Market Reactions and Future Outlook - The article notes that the French market regulator's ruling on Bolloré SE's entanglement with Vivendi has led to a 14% increase in Vivendi's share price [14]. - AVI Global Trust's strategy includes periodically buying back its own shares to maintain shareholder satisfaction and mitigate the risk of forced liquidation [18][19].

Core Insights - The report from CMB International highlights the release of the first batch of innovative pharmaceutical technology medical insurance payment incentive catalog by Zhejiang Province, which is expected to alleviate the challenges of innovative drugs entering hospitals [1] - Despite the Trump administration's announcement of a 100% tariff on imported innovative drugs, the overall impact on China's pharmaceutical industry chain is considered manageable, with a recommendation to monitor subsequent developments [1] - The upcoming ESMO conference in mid to late October is noted as a key event, with a focus on companies such as CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (688331.SH) that are expected to release significant data [1] Industry Summary - The Hong Kong pharmaceutical sector has shown relatively flat performance in September, but with increasing industry catalysts such as academic conferences and favorable policy implementations in October, a market rebound is anticipated [1] - The report recommends focusing on specific segments: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have rich short-term catalysts and their valuations do not yet reflect the core value of major products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and marginal recovery in financing [1]

Core Insights - The public fund industry has experienced a fruitful year in the structural bull market leading up to Q3 2025, with active equity funds making a significant comeback [1] - A total of 53 funds have achieved over 100% returns year-to-date, with active equity funds accounting for 42 of these, highlighting the effective strategies of fund managers in high-growth sectors like technology and innovation [2][4] - Gold ETFs have emerged as the standout performers in the commodity fund sector, with all 14 gold ETFs showing gains exceeding 40% year-to-date [5] Fund Performance - The top-performing fund, managed by Ren Jie, is the Yongying Technology Smart Selection A, with a return of 194.49%, heavily invested in the overseas computing power industry [2] - The second-best performer is the Huatai-PineBridge Hong Kong Advantage Selection A, achieving a return of 155.09%, focusing on Hong Kong's innovative pharmaceutical stocks [2] - Other notable funds include the China Europe Digital Economy A with a return of 140.86%, and two additional funds with returns of over 128% [3] Gold ETF Highlights - Gold ETFs have shown remarkable performance, with the top two funds achieving returns of 41.48% and 41.47% respectively [5] - Over the past three years, these gold ETFs have accumulated returns exceeding 110%, indicating strong long-term investment potential [6] - The recent surge in international gold prices, reaching a high of $3922.7 per ounce, is expected to further enhance the investment value of gold [6] Asset Allocation Outlook - Looking ahead to Q4, market sentiment remains high, with structural opportunities continuing to emerge, although some signs of overvaluation are noted [7] - Investment strategies may shift from growth to cyclical and consumer sectors, with a focus on underperforming cyclical stocks that may benefit from policy changes [8] - The ongoing AI technology revolution is expected to provide a premium for related assets, despite current high valuations [8][9] - The bull market trend is anticipated to continue, with a focus on emerging technologies and cyclical financials, particularly in the Hong Kong market [9]

Core Viewpoint - The public fund industry has experienced a fruitful year in the structural bull market, with active equity funds achieving remarkable performance, particularly in the AI computing and innovative pharmaceutical sectors, leading to a significant number of funds doubling their returns [1][3]. Group 1: Performance of Active Equity Funds - A total of 53 funds have seen their returns exceed 100% year-to-date as of September 30, with 42 of these being active equity funds, highlighting the fund managers' effective strategies in popular sectors like technology growth [3][4]. - The top-performing fund, managed by Ren Jie, achieved a return of 194.49%, heavily investing in the overseas computing industry chain, with significant contributions from stocks like Shenghong Technology, which surged 581% this year [3]. - Other notable funds include Zhang Wei's fund with a 155.09% return, focusing on Hong Kong innovative pharmaceuticals, and Feng Ludan's fund with a 140.86% return, both demonstrating strong performance in their respective sectors [3]. Group 2: Gold ETFs Performance - Gold ETFs have emerged as the standout performers in the commodity fund sector, with all 14 gold ETFs showing year-to-date gains exceeding 40% as of September 30 [6]. - The top gold ETFs, managed by Zhao Xu and Rong Ying, reported returns of 41.48% and 41.47%, respectively, reflecting the strong investment value of gold amid rising international gold prices [6][7]. - Over the past three years, these gold ETFs have accumulated returns exceeding 110%, indicating their robust long-term investment potential [7]. Group 3: Asset Allocation Outlook for Q4 - Looking ahead to Q4, several fund companies have provided asset allocation recommendations, suggesting a focus on growth sectors initially, followed by cyclical and consumer stocks, and finally stable dividend-paying stocks [9][10]. - The ongoing structural opportunities in the market are expected to continue, with a particular emphasis on technology, innovative pharmaceuticals, and sectors benefiting from supply-side improvements, such as new energy and chemicals [10][12]. - Companies like Guotai Fund maintain a bullish outlook on the market, emphasizing the continued importance of emerging technologies and the potential for recovery in sectors like renewable energy due to policy changes [11][12].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和黃醫藥（中國）有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00013 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | 本月底法定 ...

Core Insights - The public fund industry has experienced a fruitful year in the structural bull market, with active equity funds making a significant comeback, particularly supported by the AI computing and innovative pharmaceutical sectors [1][2]. Group 1: Fund Performance - A total of 53 funds have achieved over 100% returns year-to-date as of September 30, with 42 of these being active equity funds, showcasing the fund managers' effective strategies in high-growth sectors [2][4]. - The top-performing fund, managed by Ren Jie, achieved a return of 194.49%, heavily investing in the overseas computing industry chain, with significant contributions from stocks like Shenghong Technology, which surged 581% this year [2][3]. - Other notable funds include Zhang Wei's fund with a 155.09% return, focusing on Hong Kong's innovative pharmaceuticals, and Feng Ludan's fund with a 140.86% return, both capitalizing on the AI industry chain [3]. Group 2: Commodity Performance - Gold ETFs have emerged as the standout performers in the commodity fund sector, with all 14 gold ETFs showing gains exceeding 40% year-to-date, driven by rising international gold prices [5][6]. - The highest-performing gold ETFs, managed by Zhao Xu and Rong Ying, reported returns of 41.48% and 41.47%, respectively, reflecting strong long-term investment value [5][6]. Group 3: Market Outlook - Looking ahead to Q4, several fund companies suggest maintaining a focus on growth sectors while also considering cyclical and consumer stocks, as the market has already seen significant gains [7][8]. - The ongoing AI technology innovation is expected to provide a premium valuation for related assets, despite potential short-term volatility [8][9]. - The overall market sentiment remains bullish, with continued optimism for emerging technologies and cyclical financial sectors, particularly in the context of the "anti-involution" policies that may enhance competition in the renewable energy sector [9].

Core Insights - Hutchison China MediTech Limited (和黄医药) will present updated research data on its self-developed compounds at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting in Berlin from October 17 to 21, 2025 [1] Group 1: Research Presentations - The FRUSICA-2 registration study results for fruquintinib combined with sintilimab in the second-line treatment of locally advanced or metastatic renal cell carcinoma will be presented in a mini-oral session [1] - Further analysis results of the FRUSICA-1 study on fruquintinib for endometrial cancer, as well as the SACHI and SAVANNAH studies on savolitinib for non-small cell lung cancer, will be showcased in poster presentations [1]

Core Viewpoint - The company announced that it will present updated research data on its self-developed compounds at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting in Berlin from October 17 to 21, 2025 [1] Group 1: Research Presentations - The FRUSICA-2 registration study results of fruquintinib combined with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma will be presented in a mini-oral session [1] - Further analysis results of fruquintinib for endometrial cancer from the FRUSICA-1 study will be showcased in a poster presentation [1] - The SACHI and SAVANNAH studies analyzing savolitinib for non-small cell lung cancer will also be presented in the poster session [1]

Core Viewpoint - The company, Hutchison China MediTech Limited (和黄医药), announced that it will present updated research data on its self-developed compounds at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting in Berlin from October 17 to 21, 2025 [1] Group 1: Research Presentations - The FRUSICA-2 registration study results for fruquintinib combined with sintilimab in the second-line treatment of locally advanced or metastatic renal cell carcinoma will be presented during a mini-oral session [1] - Further analysis results of the FRUSICA-1 study on fruquintinib for endometrial cancer, as well as the SACHI and SAVANNAH studies on savolitinib for non-small cell lung cancer, will be showcased in the poster presentation session [1]